The Roche troika was first marketed with 1.5 billion varieties

▍1.5 billion varieties, the first domestic imitation heavy-weight listingDecember 9, the State Drug Administration issued a message, approved Qilu Pharmaceutical Co., Ltd. developed beva zhu single anti-injection (commodity name: Anda) listing application.The drug is the first approved beva bead monobial-like drug, mainly used for the treatment of advanced, metastatic or relapse non-small cell lung cancer, metastatic colorectal cancer patients.It is understood that Beval pearl single resistance developed by Roche, in 2004 was first approved by the U.S. FDA listed, has now become the European and American market anti-tumor treatment of the basic drug. In February 2010, Beval Pearl Single Resistance was allowed to enter the Chinese market.Beva bead monoantigen (Avivatin) is a humanized anti-VEGF monoclonal antibody, is Roche's world's first widely used anti-angiogenesic drugs for a variety of tumors, by blocking VEGF to inhibit the angiogenesic tumor, cut off the blood supply to the tumor area, inhibit the growth and metastasis of the tumor, thereby producing anti-tumor effect.According to Insight's sales database, domestic beval beads have sales of approximately $1.5 billion in 2017.▍ Roche, the troika was snipeedBeval beads single resistance, injection with curt beads single resistance and Lytoxi single resistance as Roche's troika, the performance in China is equally impressive - The three in 2018 total sales of more than 9.7 billion yuan, multinational giant Roche occupies China's public medical institutions terminal anti-tumor monolith resistance 80% of the market.According to the PDB database, in 2016 there were less than 100,000 beva beads in 22 sample hospitals in China, and at the end of 2017, as the patent protection period was near, Roche's Beval pearl single resistance was significantly reduced through national negotiations and entered the national health insurance directory. Even so, the price of imported beval beads is still around 2000 yuan, the monthly cost of medication for cancer patients is more than 10,000 yuan.Specifically, roche's Avetin 100mg:4ml list price was $5,398, which fell to $1998 (100mg:4ml/bottle) on July 19, 2017. With a 63% decline, Avetin sales are up 205% in 2018.Previously, some experts have said that if the product wants to enter health insurance, the existence of the first imitation will make the government cut prices more, the patent cliff effect is more obvious, the domestic first imitation listing, or will promote Avetin's further price reduction.In addition to beva bead mono-resistance, lytosi mono-resistance and curt-pearl mono-resistance are also sniping. On February 25th, the lytoxidan anti-injection (commodity name: Hanlikang) developed by Shanghai Fuhong Hanxuan Biopharmaceutical Co., Ltd. was approved for listing, mainly for the treatment of non-Hodgkin's lymphoma. Sansheng Guojian's application for the listing of recombinant anti-HER2 humanized monoclonal antibody (CXSS1800023) for injection was accepted by CDE contractor in September 2018.It is precisely because of these single-resistant varieties overseas faster release speed and higher sales amount, attracted the attention of many domestic research and development enterprises, and the development of bio-like objects more in line with the domestic enterprises from imitation to innovative ideas, resulting in domestic enterprises in beval beads single-resistance, Adamo single-resistance, lyxi single-resistant heavy biosimilar drug research and development competition is extremely fierce.In the case of Beval Pearl Monoantiton, Insight database variety details show that more than 30 domestic research, of which 3 enterprises are in the listing application, 18 are in clinical trials, 10 are in the approved clinical state, 5 are in clinical applications, the overall competition is very fierce.▍ first imitation, pharmaceutical representative selection opportunitiesthe industry as a whole from high sales model to high research and development model in the process of transformation, generic competition intensified, how to grab products and markets to become enterprises must consider the layout direction, at this time, the first imitation, difficult to imitate and improve the new drug, because of technical barriers to obtain a more relaxed competitive environment, become the future choice of pharmaceutical representatives.Recently, we have entered the intensive harvest period of the first imitation varieties, and a number of pharmaceutical companies have been approved for the first imitation. 　　On November 29, Abao Pharmaceutical Group Co., Ltd. announced that it had received approval from the State Drug Administration to issue the "Drug Registration Approval" of the agritin tablets, becoming the first enterprise in China to obtain the registration approval of agritin tablets. 　　On November 21st, insight database showed that Jiangsu Hengrui class 3 generic drugs? Hydrochloric acid ascetamine injection? Change the status of listing applications in China to ? Approval completed - the pending certification ?—— round of supplementary information and clinical trial site verification, is expected to be approved for listing. 　　On November 7, the State Drug Administration announced that the country's first Adamo monobial-like drugs were approved for market. It is understood that Baiotai Biopharmaceutical Co. , Ltd. developed Adamo single anti-injection solution (commodity name: Greli), is the first approved Adamo single anti-biosimilar drug, adaptive to strong straight spina bifida, rheumatoid arthritis and psoriasis and other autoimmune diseases. 　　In mid-October, Haussen Pharmaceuticals received a "Drug Registration Approval" approved by the State Drug Administration for the injection of fusapiram double glucosamine (commodity name: tannin®) to prevent acute and delayed nausea and vomiting caused by chemotherapy. As the first and only approved listed Fusapitan double glucosamine, Tannen ® in accordance with the chemical drug new category 3 declaration, as if through the consistent evaluation. (Cypress Blue)